NeOnc Technologies Holdings, Inc. Common Stock

NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) is a clinical-stage, pre-revenue biopharmaceutical company developing therapies for central nervous system cancers, including high-grade glioma, glioblastoma and brain metastases. It has two lead investigational programs. NEO100 is a highly purified form of perillyl alcohol given intranasally, designed as a non-invasive route to the brain that addresses delivery across the blood-brain barrier. It has reported positive topline Phase 2a results in recurrent IDH1-mutant high-grade glioma and is also being studied in a pediatric trial (NEO100-03). NEO212 is an oral conjugate of temozolomide and NEO100 being studied in TMZ-resistant recurrent glioblastoma and brain metastases. It has completed Phase 1 dose escalation and is advancing toward Phase 2 under an FDA IND, with a planned transition from capsule to tablet. The company exclusively licenses a worldwide patent portfolio from the University of Southern California covering NEO100, NEO212 and other drug candidates and delivery approaches. NeOnc is expanding internationally in Abu Dhabi, where both candidates received Investigational New Drug authorizations in June 2026, and it signed a non-binding MoU with the Department of Health – Abu Dhabi in October 2026. Operations are funded through equity offerings, an at-the-market program and a related-party line of credit. Updated Nov 5, 2026